BIOCHINA, organized by EnmoreBIO, is the largest bio convention in China, covering the full ecosystem in Chinese bio industry, By associating with the scientific research, biotech and biopharma, government regulation agencies, and clinical institutions, CDMOs, CROs, the convention lined up each sectors aims to advance the bio ecosystem in China.

BIOCHINA2024 featured five major professional exhibition halls, 839 speakers, 128 forums, and served 27,931 participants, including 1,194 professional buyers, 1424 investors, 5676 partnering meetings on March 2024. Building on the BIOCHINA project, we also run online media channels in China, and webinars internationally.

The attendees of BIOCHINA included 28k delegates from

Biotech: Antibody Drug & ADC, Cell and Gene Therapy(CGT), Nucleic Acid Drug, Peptide, Vaccine, Small molecule Innovative drug and other, such as Kechow Pharma , Blueray Biopharma , Shanghai Huaota Biopharmaceutical, Huabo Biopharm, Convergen, Linno Pharmaceuticals Inc., ACCESS Health, Shanghai Ruling Biomedical, Shanghai Yiyan Biotechnology, Mainstream Source Biotechnology , CARGENE BIOPHARMA , Teruisi , Harbour BioMed , LEADERMEDOPKO HEALTH, Cure Genetics Co., Limited., Innovent Biologics, Immune-Onc Therapeutics, Inc., Harbour BioMed, CARsgen Therapeutics, Hua Medicine(Shanghai)Ltd., CanSino Biologics Inc., LION TCR, Kira Pharmacetuicals, Kira Pharmacetuicals, Betta Pharmaceuticals, Junshi Pharma, Henlius, Hua Medicine, Akeylink Biotechnology, BaseCure (Wuxi) Biotechnology, Adlai Nortye, Shanghai Yituo Pharmaceutical Technology, MegaPro Biomedical, Genfleet Therapeutics, Hopstem Biotechnology Inc…

Pharma/MNC: AbbVie, Amgen, Astellas, GSK, Johnson & Johnson, Moderna, Pfizer, Sanofi, Teva Pharmaceuticals, Shanghai Huanghai Pharmaceutical Co.,Ltd., Zhuhai United Laboratories Co.,Ltd., Zhuhai United Laboratories Co.,Ltd., Shanghai Pharma Innovation Center, Zhejiang Hisun Pharmaceutical Co., Ltd., Fosun Pharma, CR PHARMA, Betta Pharmaceuticals Co., Ltd., Betta Pharm, POLY PHARM, Jiangsu Aosaikang Pharmaceutical Co.,Ltd., POLY PHARM, SPH TECHPOOL, Tasly, Qilu Pharma , HAN HUI Pharmaceuticals, Hemony Pharmaceutical, Shanghai Pharma, Shanghai Yidian Pharma, Shanghai Cell Therapy Group, Sunshine Guojian, Simcere Pharmaceutical, CR ANJIU , KEXING BIOPHARM , CR PHARMA ……

Investment Institutions:

ZHONGAN HEALTH, FItCn International Investment Holding(Shenzhen) Co.,Ltd., Ping An Capital, CITIC SECURITIES, Shanghai Yunqi Capital Management Co.,Ltd., Simple Capital, GLP, IDA Ireland, Huakai(Fujian)Equity, Qiji Investment, Asia Asset Hongma Investment Management Co., Ltd, Ascendum Capital, Index Capital, Yuansheng Venture Capital, Vivo Capital, SDIC Fund, Hanne Capital, Jiaxing South Lake Fund and Investment Co.,Ltd., PIVOTAL BIOVENTURE PARTNERS, Shanghai Angju Asset Management Co., Ltd, Hangzhou Hongye Yuanhang Equity Investment Partnership, ny Innovation (Beijing) Investment Management, Tianfeng Healthcare, BioTrack Capital, Bluestone Capital, JUNQI GROUP, JRich Capital Co.Ltd, Pfizer Investment Co.,Ltd, Qiming Venture Partners, ESSENCE SECURITES, HSBC Bank, GS CAPITAL, ENNOVATION VENTURES, Jiale Capital, KLT Fund, PIVOTAL BIOVENTURE PARTNERS, China Merchants Bank, PIVOTAL BIOVENTURE PARTNERS, CCB Private Equity Investment Management Co.,Ltd., Co-win Ventures, YONGHUA Capital, Delos Capital, Dedao Investment Management Co.,Ltd., MSQ ventures, Virtus Inspire Ventures, Wenrun Investment, ICBC, Zhongke Fortune Management Co.,Ltd., Shanghai Angju Asset Management Co., Ltd, DASCAPITAL, FreesFund, Guangzhou Haotou Investment Management Co.,Ltd, Guotai Junan Securities, Index Capital, Cathay Fortune Corp., CCB(Beijing)Investment Fund Management Co.,LTD., Industrial Securities Economics and Finance Research Institute, East Fortune, Yichen Capital, ENNOVATION VENTURES, Ruifu Investment, Shanghai Rehabilitation Capital, Shanghai Niuhu Asset Managemen, Shenzhen Capital Group Co.,Ltd., SHENZHEN XIPENG VENTURE CAPITAL, PARTNERSHID, Linear Venture, Xinxi Capital, Zhijie Capital, 3E Bioventures, CBC Group, Morningside Ventures, Morningside Ventures, DASCAPITAL, HANNE CAPITAL, Hongfeng Venture, Huachuang Yida, Huagai Capital, Focus Fund, Legend Capital, KAITAI CAPITAL, Qiming Venture Partners, Quan Capital, Shanghai Angju Asset Management Co., Ltd, Shenzhen Hi-tech Investment Group Co.,Ltd., Xinxi Capital, Xingxin Innovation Capital, Zhifu Capital Management Co.,Ltd., Fortune Capital, Legend Capital, Elikon Venture, nty Innovation (Beijing) Investment Management, SincereVC.,Ltd, Shenyin&Wanguo Investment Co.Ltd, Grand MountCapital…